Celadon Pharmaceuticals Plc

("Celadon", the "Group" or the "Company")

Termination of Credit Facility

London, 08 April 2025 - The Company today announces it intends to terminate its new committed credit facility, details on the facility were disclosed in an announcement by the Company on 26 February 2025 (the "Facility"). Celadon no longer expects to receive any funds under the Facility. As part of the termination, the Company will apply for the floating charge over the assets of Celadon to be removed.

All other matters as set out in the 31 March 2025 funding update announcement remain valid, including continued engagement with alternative providers of finance to provide working capital.

Enquiries:

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website www.celadonpharma.com

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.